What is the equity of Pharmaust this year?
Pharmaust has equity of 3.89 M AUD this year.
Pharmaust Equity 2024
Pharmaust Equity
3.89 M AUD
Ticker
PAA.AX
ISIN
AU000000PAA1
WKN
A0DNJ3
In 2024, Pharmaust's equity was 3.89 M AUD, a -50.42% increase from the 7.84 M AUD equity in the previous year.
Pharmaust Aktienanalyse
What does Pharmaust do?
Pharmaust Ltd is a biotechnology company based in Perth, Australia. The company was founded in 2001 by Dr. Roger Aston and Dr. Paul Gavin as a spin-off from the School of Biomedical Sciences at Curtin University of Technology. Their goal was to advance the discovery and development of novel therapeutics and diagnostics for cancer and autoimmune diseases. Pharmaust's history began with the discovery of a novel molecule called PPL-1 by Dr. Roger Aston. This molecule had the potential to serve as a cancer therapeutic as it could inhibit the release of tumor cells. Pharmaust researchers held patents for PPL-1 in the US, Europe, and Australia. Another important milestone for Pharmaust was the discovery of a new class of compounds with potential cancer and autoimmune therapeutics known as PPL-100, PPL-300, and PPL-400. Pharmaust's business model is focused on bringing novel drugs and diagnostics to market and selling them. Pharmaust aims to use its technologies to reduce the high costs of drug research and ultimately help patients suffering from serious diseases. Pharmaust has several divisions, including: - Pharmaceutical research and development: Pharmaust is working to discover and develop new therapeutics and diagnostics, particularly for the treatment of cancer and autoimmune diseases. - Clinical research: Pharmaust conducts clinical trials to assess the safety and efficacy of its drugs and obtain the necessary approvals for market authorization. - Licensing and marketing: Pharmaust markets its products in Australia and other countries, and licenses its technologies to other biopharmaceutical companies to generate additional revenue. Pharmaust's current product portfolio includes two main products sold under the brand names Monepantel and PPL-003. Monepantel is an anthelmintic used to treat parasite infestation in livestock such as sheep and goats. PPL-003 is an immunotherapy for the treatment of skin cancer, currently being tested in clinical trials. In particular, Pharmaust has developed a therapy in recent years that supports immunotherapy and works closely with clinics and payers to further develop and market their therapy. Pharmaust has received numerous awards and recognitions in recent years, including the award for Perth's Best Emerging Company and recognition from the Western Australian Industry and Export Awards (WAIEA) and the Australasian Society for Stem Cell Research (ASSCR). In conclusion, Pharmaust Ltd remains committed to saving and improving lives. The company sees a promising future in the discovery, development, and marketing of novel therapeutics and diagnostics for the treatment of serious diseases. By integrating four different drug classes, Pharmaust is working on a range of early-stage development projects that have the potential to help patients suffering from various diseases. Pharmaust ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Pharmaust's Equity
Pharmaust's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Pharmaust's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Pharmaust's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Pharmaust's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Pharmaust’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Pharmaust stock
What was the equity of Pharmaust compared to the previous year?
The equity of Pharmaust has increased/decreased by -50.42% decreased compared to the previous year.
What impact does a high equity have on investors of Pharmaust?
A high equity is advantageous for investors of Pharmaust as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Pharmaust?
A low equity can be a risk for investors of Pharmaust, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Pharmaust affect the company?
An increase in equity of Pharmaust can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Pharmaust affect the company?
A reduction in equity of Pharmaust can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Pharmaust?
Some factors that can affect the equity of Pharmaust include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Pharmaust so important for investors?
The equity of Pharmaust is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Pharmaust take to change the equity?
To change equity, Pharmaust can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Pharmaust pay?
Over the past 12 months, Pharmaust paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pharmaust is expected to pay a dividend of 0 AUD.
What is the dividend yield of Pharmaust?
The current dividend yield of Pharmaust is .
When does Pharmaust pay dividends?
Pharmaust pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Pharmaust?
Pharmaust paid dividends every year for the past 0 years.
What is the dividend of Pharmaust?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Pharmaust located?
Pharmaust is assigned to the 'Health' sector.
Wann musste ich die Aktien von Pharmaust kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Pharmaust from 9/10/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.
When did Pharmaust pay the last dividend?
The last dividend was paid out on 9/10/2024.
What was the dividend of Pharmaust in the year 2023?
In the year 2023, Pharmaust distributed 0 AUD as dividends.
In which currency does Pharmaust pay out the dividend?
The dividends of Pharmaust are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Pharmaust
Our stock analysis for Pharmaust Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharmaust Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
